Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.

Abstract: The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.

Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indole-1-yl-(1H)-quinoline-2-one and indole-3-yl-(1H)-quinoline-2-one type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.

Abstract: The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.

Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.

Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.

Abstract: The invention relates to a compound of the formula (I) in which: R1, R2 and R3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R4 is a hydrogen atom; R5 and R6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Abstract: The present invention relates to compounds of formula (I) below in which: —R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R2 and R4 represent, independently of one another, a hydrogen atom or a methoxy group optionally substituted by one or more fluorine atoms, —A represents a ring chosen from the group comprising aryl and heteroaryl groups, said ring possibly being substituted by or fused to a heterocycle, —X represents a nitrogen atom or a CH group, and —Z1 represents a hydrogen atom or a halogen atom, preferably fluorine, and —Z2 represents a hydrogen atom, a halogen atom, preferably fluorine, a C1 to C4 alkyl group, an aryl group or a —CN, —SO2NR12R13, —SO2R9, —COOR15 or —COR15 group, and also to the pharmaceutically acceptable salts thereof, the isomers thereof and the prodrugs thereof.

Abstract: The invention relates to a compound of the formula (I) in which: R1, R2 and R3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R4 is a hydrogen atom; R5 and R6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Abstract: Compounds of formula (I): wherein: R1 represents hydrogen, (C1-C6)alkyl, (C1-C6)aminoalkyl or (C1-C6)hydroxyalkyl, R2 represents hydrogen, or R1 and R2, together with the carbon atoms carrying them, form a carbon-carbon bond, R3 represents hydrogen, R4 represents hydrogen, methyl or (C3-C6)alkyl, (C1-C6)aminoalkyl, (C1-C6)hydroxyalkyl, aryl-(C1-C6)alkyl or heterocycloalkyl-(C1-C6)alkyl, or R3 and R4 together with the carbon atoms carrying them, form a carbon-carbon bond, R5, R6, R7 and R8 represent hydrogen, or a pair of geminal substituents (R5 and R6 and/or R7 and R8) form an oxo, thioxo or imino group, R9 represents hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, cyano, nitro, (C1-C6)polyhaloalkyl or optionally substituted amino, R10 and R11 represent hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, cyano, nitro, (C1-C6)polyhaloalkyl or optionally substituted amino, n represents an integer between 0 and 4 inclusive, m represents an integer between 0 and 2 inclusive, p represents an

Abstract: Compounds of formula (I): wherein: A represents a divalent radical: wherein: Z represents an oxygen atom or a sulphur atom, R6 represents a hydrogen atom, an alkyl, alkenyl, arylalkyl or polyhaloalkyl group or a substituted, linear or branched alkyl chain, represents a single bond or a double bond, R1, R2, R3 and R4 represent a hydrogen or halogen atom, an alkyl, alkoxy, hydroxy, cyano, nitro, polyhaloalkyl or optionally substituted amino group, or a linear or branched alkyl chain substituted by one or more groups, R5 represents a hydrogen atom or an alkyl, aminoalkyl or hydroxyalkyl group, X and Y represent a hydrogen atom or an alkyl group, Ra, Rb, Rc and Rd represent a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, cyano, nitro, polyhaloalkyl, optionally substituted amino group, or a substituted, linear or branched alkyl chain, Re represents a hydrogen atom or an alkyl, arylalkyl or alkenyl group or a substituted, linear or branched alkyl chain, their enantiomers, diastereoisomers